Confusing naming conventions, uncertain ROI and growing compliance concerns are among the barriers to wider adoption.

Life sciences companies around the globe are grappling with the question of whether and how to deploy generative artificial intelligence (GenAI) tools, including use in streamlining company processes.

Leeron is a New York-based writer who specializes in covering technology for small and mid-sized businesses. Her work has been featured in publications including Bankrate, Quartz, the Village Voice, ...